Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
H S RugoM OliveiraS J HowellF DalencJ CortesH L GomezX HuK L JhaveriP KrivorotkoS LoiblS Morales MurilloZ NoweckiM OkeraY H ParkJ SohnM ToiH IwataS YousefL ZhukovaJ LoganK TwomeyM KhatunC M D'CruzN C TurnerPublished in: ESMO open (2024)
Frequent AEs associated with PI3K/AKT pathway inhibition occurred early and were manageable. The low rate of treatment discontinuations suggests that, when appropriately managed, these AEs do not pose a challenge to clinical benefit.